To determine whether the large volumes of cardiotomy suction which occur during long perfusions can obscure the hematological advantage of the membrane oxygenator (MO) over the bubble oxygenator (BO), we studied 23 patients undergoing a coronary artery bypass grafting operation with an expected perfusion time of 3 hours (MO group, N = 10, SciMed spiral coil; BO group, N = 13, Shiley 100-A). During MO perfusion we found significantly higher platelet numbers, better platelet function (adenosine diphosphate-induced platelet aggregation), and less hemolysis (plasma hemoglobin), than during the BO perfusion. After the MO perfusion we measured significantly shorter bleeding times (Simplate II) and fewer transfusions of blood products. However, blood loss and whole-blood transfusions 18 hours after perfusion did not differ significantly between both groups. So in coronary artery bypass grafting operations with long perfusion times (mean, 3 hours), the MO still causes significantly less platelet and erythrocyte damage than the BO, despite the large volumes of cardiotomy suction known to occur during these operations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0003-4975(10)62773-7 | DOI Listing |
Front Oncol
December 2024
Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Targeted Protein Degradation (TPD) represented by Proteolysis-Targeting Chimeras (PROTAC) is the frontier field in the research and development of antitumor therapy, in which oral drug HP518 Receives FDA Proceed Authorization for its IND Application for Prostate Cancer Treatment. Recently, molecular glue, functioning via degradation of the target protein is emerging as a promising modality for the development of therapeutic agents, while exhibits greater advantages over PROTAC, including improved efficiency, resistance-free properties, and the capacity to selectively target "undruggable" proteins. This marks a revolutionary advancement in the landscape of small molecule drugs.
View Article and Find Full Text PDFData Brief
February 2025
MARS Lab, Department of Computer Science and Engineering, Daffodil International University, Daffodil Smart City, Birulia, Dhaka 1216, Bangladesh.
Anemia is a critical medical condition in public health concern in tropical and subtropical areas, and understanding its hematological changes is crucial for improving diagnosis, treatment, and prognosis.It manifests through symptoms like weakness, fatigue, pale skin, and shortness of breath due to insufficient hemoglobin or red blood cells to carry adequate oxygen, with severe cases leading to complications such as chest pain. Common causes include blood loss, chronic diseases, and iron and vitamin deficiencies.
View Article and Find Full Text PDFItal J Pediatr
January 2025
Pediatric Hematology and Oncology, SBU Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
Background: Rare bleeding disorders (RBDs) include fibrinogen (Factor I), prothrombin (Factor II), Factor V(FV), combined Factor V and Factor VIII, Factor VII, Factor X, Factor XI, Factor XII, and Factor XIII deficiencies. This group accounts for 3-5% of all factor deficiencies. Different symptoms may occur, ranging from mild or moderate bleeding to serious and life-threatening bleeding, which may not be related to the factor level.
View Article and Find Full Text PDFJ Transl Med
January 2025
Evvivax Biotech, Via Castel Romano 100, 00128, Rome, Italy.
In the past decades, Chimeric Antigen Receptor (CAR)-T cell therapy has achieved remarkable success, leading to the approval of six therapeutic products for haematological malignancies. Recently, the therapeutic potential of this therapy has also been demonstrated in non-tumoral diseases. Currently, the manufacturing process to produce clinical-grade CAR-T cells is complex, time-consuming, and highly expensive.
View Article and Find Full Text PDFJ Med Chem
January 2025
Department of Chemistry, The Hong Kong University of Science and Technology, Hong Kong SAR 999077, China.
CDK4/6 inhibitors are effective in treating HR/HER2 breast cancer but face limitations due to therapeutic resistance and hematological toxicity, particularly from strong CDK6 inhibition. To address these challenges, designing selective inhibitors targeting specific cyclin-dependent kinases (CDK) members could offer clinical advantages and broaden CDK inhibitor indications. However, the highly conserved binding pockets of CDKs complicate selective targeting.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!